The goal is long-term resilience
Semaglutide offers promising benefits for weight loss and blood sugar control and improving cholesterol levelsan essential factor in cardiovascular health
Obesity & ROSE-010: The Future of Weight Loss Maintenance The GLP-1 Dilemma: Maintaining Weight Loss & Seeking Alternative Weight Loss Options GLP-1 therapies have helped millions lose weight, yet 60-85% of patients discontinue within two years due to: Tolerability Issues Over 50% of GLP-1 patients stop due to nausea, vomiting, or GI side effects Insurance & Cost Barriers Insurance coverage remains inconsistent, limiting long-term access Reaching Their Goa l Many patients lose their desired weight and no longer need daily or weekly injections The Problem
For instance, Paxlovid may interact with drugs used to treat irregular heartbeats, blood pressure, high cholesterol, and mental health conditions
Maintenance phase: Once the initial phase is completed, the frequency of lipotropic injections may be reduced